<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426140</url>
  </required_header>
  <id_info>
    <org_study_id>CEPO906A2122</org_study_id>
    <nct_id>NCT00426140</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.</brief_title>
  <official_title>An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to characterize the distribution, metabolism, and&#xD;
      elimination (ADME) of Patupilone after a single intravenous administration in patients with&#xD;
      advanced solid tumor malignancies&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the pharmacokinetic profile of patupilone including any potential metabolite(s) in blood/plasma as well as the total radioactivity in blood and plasma.</measure>
    <time_frame>one week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability will be assessed by AEs, SAEs and out of range lab values.</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological scans will also be completed at approximately 6 weeks to asses anti-tumor activity.</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Advanced Malignancies</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>EPO906</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patupilone</intervention_name>
    <arm_group_label>EPO906</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years or older&#xD;
&#xD;
          2. World Health Organization (WHO) Performance Status Score of: 0- you are fully active&#xD;
             and more or less as you were before your illness, 1 - you cannot carry out heavy&#xD;
             physical work, but can do anything else.&#xD;
&#xD;
          3. Adequate hematological laboratory parameters&#xD;
&#xD;
          4. No major impairment of renal or hepatic function&#xD;
&#xD;
          5. Female patients must have a negative serum pregnancy test at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe and/or uncontrolled medical disease;&#xD;
&#xD;
          2. Severe cardiac insufficiency with uncontrolled and/or unstable cardiac or coronary&#xD;
             artery disease;&#xD;
&#xD;
          3. Known diagnosis of human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          4. Presence of any other active or suspected acute or chronic uncontrolled infection;&#xD;
&#xD;
          5. Symptomatic brain metastases or leptomeningeal disease.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center, Institution for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2941</url>
    <description>Results can be found for CEPO906A2122 on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>EPO</keyword>
  <keyword>Patupilone</keyword>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilone B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

